Patents Assigned to ICOS
  • Therapeutic uses for MDC and MDC antagonists
    Publication number: 20050238647
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C—C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.
    Type: Application
    Filed: April 6, 2004
    Publication date: October 27, 2005
    Applicant: ICOS CORPORATION
    Inventors: Patrick Gray, David Chantry, Michael Deeley
  • Communications apparatus and method
    Patent number: 6950625
    Abstract: A method of reusing frequency bands between base stations of a terrestrial mobile communications network and a satellite communications network, comprising allocating the frequency bands using integrated resource management and other mitigation techniques in a such a way as to minimize interference between both the systems, thus making optimum usage of valuable frequency spectrum.
    Type: Grant
    Filed: April 16, 2001
    Date of Patent: September 27, 2005
    Assignee: ICO Services Limited
    Inventors: Paul Lucian Regulinski, Govindan Vishnu Nampoothiri, Patrick Chomet
  • Inhibitors of human phosphatidyl-inositol 3-kinase delta
    Patent number: 6949535
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K? plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K?, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity. Methods of using PI3K? inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K? inhibitory compounds to inhibit PI3K?-mediated processes in vitro and in vivo.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: September 27, 2005
    Assignee: ICOS Corporation
    Inventors: Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver
  • Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
    Patent number: 6943166
    Abstract: The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3?,5?-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 13, 2005
    Assignee: Lilly ICOS LLC.
    Inventors: William Ernest Pullman, John Steven Whitaker
  • PARP inhibitors
    Patent number: 6924284
    Abstract: The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula: or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q1, Q2 and Y are those defined herein.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: August 2, 2005
    Assignees: ICOS Corporation, Deltagen Research Labs, LLC
    Inventors: Graham Beaton, Wilna J. Moree, Jaimie K. Rueter, Russell S. Dahl, David L. McElligott, Phyllis Goldman, Anthony J. Demaggio, Erik Christenson, Dan Herendeen, Kerry W. Fowler, Danwen Huang, Jaimie E. Bertino, Lisa H. Bourdon, David J. Fairfax, Qin Jiang, Helge A. Reisch, Ren Hua Song, Pavel E. Zhichkin
  • Satellite communications system and user terminal providing path diversity
    Patent number: 6920323
    Abstract: In a satellite communications system, where a user terminal 10, on the surface of the earth 12, can be in diversity communication to an earth station 18 via two orbiting satellites 14, 16 at once, and there is a need, at some time, when one of the two satellites 14, 16 orbits our of range, to engage another satellite 22 in its place, the user terminal 10 is operative to suppress TDMA timeslots in its communications with the two satellites 14, 16 to listen and report on broadcast messages from another satellite 22, the suppressed timeslots being based on an assessment of which of the two satellites has the largest path attenuation.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: July 19, 2005
    Assignee: ICO Services Ltd.
    Inventor: Mark Grayson
  • Pyrazino[1?,2?:1,6]pyrido[3,4b]indole derivatives
    Patent number: 6911542
    Abstract: Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: June 28, 2005
    Assignee: Lilly Icos LLC.
    Inventors: Mark W. Orme, Jason Scott Sawyer, Lisa M. Schultze, Alain Claude-Marie Daugan, Francoise Gellibert
  • Condensed pyrazindione derivatives
    Patent number: 6903099
    Abstract: Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: June 7, 2005
    Assignee: Lilly Icos LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Lisa M. Schultze
  • Indole derivatives as PDE5-inhibitors
    Patent number: 6878711
    Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: April 12, 2005
    Assignee: Lilly Icos LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Lisa M. Schultze
  • Derivatives of 2,3,6,7,12,12a-hexahydropyrazino-[1?,2?:1,6]pyrido[3,4b]-indole-1,4-dione
    Patent number: 6872721
    Abstract: Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: March 29, 2005
    Assignee: Lilly ICOS LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan
  • Phosphodiesterase 10
    Patent number: 6864070
    Abstract: The present invention provides novel human PDE10 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE10 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE10 polypeptides. The invention further provides methods to identify binding partners of PDE 10, and more particularly, binding partners that modulate PDE10 enzyme activity.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: March 8, 2005
    Assignee: Icos Corporation
    Inventor: Kate Loughney
  • Condensed pyridoindole derivatives
    Patent number: 6858620
    Abstract: Compounds of general structural formula (I), and use of the compounds or salts or solvates thereof as therapeutic agents, are disclosed
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: February 22, 2005
    Assignee: Lilly ICOS, LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan, Romain Luc Marie Gosmini, Lisa M. Schultze
  • ?-carboline pharmaceutical compositions
    Patent number: 6841167
    Abstract: A soft capsule containing a solution or suspension of a PDE5 inhibitor, and use of the capsule in treating sexual dysfunction.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: January 11, 2005
    Assignee: Lilly Icos LLC.
    Inventors: Neil R. Anderson, Rampurna P. Gullapalli
  • Condensed pyridoindole derivatives
    Patent number: 6838456
    Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: January 4, 2005
    Assignee: Lilly ICOS LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan, Françoise Gellibert, Romain Luc Marie Gosmini
  • Cyclic GMP-specific phosphodiesterase inhibitors
    Patent number: 6825197
    Abstract: Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: November 30, 2004
    Assignee: Lilly ICOS LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer
  • Beta-carboline drug products
    Patent number: 6821975
    Abstract: A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: November 23, 2004
    Assignee: Lilly ICOS LLC
    Inventors: Neil R. Anderson, Kerry J. Hartauer, Martha A. Kral, Gregory A. Stephenson
  • Chemokine receptor materials and methods
    Publication number: 20040230037
    Abstract: The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.
    Type: Application
    Filed: February 4, 2004
    Publication date: November 18, 2004
    Applicant: Icos Corporation
    Inventors: Patrick W. Gray, Vicki L. Schweickart, Carol J. Raport
  • I-CAM related protein
    Patent number: 6818743
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated “ICAM-R”) and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Antibodies substances specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding reactions involving ICAM-R.
    Type: Grant
    Filed: September 28, 1994
    Date of Patent: November 16, 2004
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • Satellite mobile telephone cell departure prediction
    Publication number: 20040224632
    Abstract: A mobile station (4) in a satellite mobile telephone system predicts when it will move into another cell on the basis of one set of broadcast information thereby reducing the overall processing burden. The mobile station (4) can predict with a useful degree of certainty which broadcast control channel (BCCH) frequencies it should listen on when it wakes up on the basis of a stored map of the relative positions of cells. The broadcast information includes information about the current cell's (40) shape (V1, V2, V3, V4, V5, V6) and translational (T) and rotational (R) motion.
    Type: Application
    Filed: May 26, 2004
    Publication date: November 11, 2004
    Applicant: ICO Services Limited
    Inventor: Benjamin H. Hutchinson
  • ATR-2 cell cycle checkpoint
    Patent number: 6815532
    Abstract: Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: November 9, 2004
    Assignee: ICOS Corporation
    Inventors: Kate Loughney, Kathleen S. Keegan